Stockreport

AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

ARCA biopharma, Inc.  (ABIO) 
US:NASDAQ Investor Relations: arcabio.com/investors
PDF Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed f [Read more]